Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 383605
Licensor grants the exclusive, with the right to sublicense, under the Licensor Patents and the Licensor Know-How and in the Licensed Field, to research and have researched, develop and have developed, make and have made, and use and have used the Development Candidate and to research and have researched, develop and have developed, make and have made, manufacture and have manufactured, use and have used, market and have marketed, distribute and have distributed, sell and have sold, export and import for sale, and have exported or imported for sale, Drug Products in each country in the Territory.
HDAC Inhibitor Compound shall mean any Active Compound that has a specific, desired therapeutic action through its ability to bind directly to an HDAC and inhibit HDAC activity.
IC50 shall mean the concentration of a compound that reduces activity of an enzyme by 50% in a standard, validated assay.
The Cardiac Field shall mean the research, treatment, prognosis, diagnosis, prophylaxis, and monitoring of heart muscle disease.
IPSCIO Record ID: 344537
This agreement includes a non-exclusive grant back to Licensor.
Compounds means compounds that were or are identified, synthesized, discovered, designed or acquired by or on behalf of (A) Licensor or its Affiliates either prior to the date hereof or during the Term, (B) Licensee or its Affiliates during the term of the Research and Development Program, or (C) a Non-ND Partner or its Affiliates either prior to the date hereof or during the Term, but only if during the term of a Non-ND Research Program; either are HDAC Inhibitors or (b) are developed pursuant to the Collaboration (subject to the last sentence of this defined term Compound); possess certain basic drug characteristics and range of chemotypes with pan and sub-type selective HDAC inhibition characteristics, as mutually agreed to by the Parties from time to time; and are used or useful in the Field.
HDAC means HDAC Class I and HDAC Class II, collectively.
HDAC Inhibitors means Small Molecules that directly inhibit HDAC Class I or HDAC Class II enzymatic activity or which have therapeutic effect through the inhibition of HDAC Class I or HDAC Class II enzymes.
Licensor Program Compounds means the approximately(Â± 5%) 1014 Compounds.
Field means the treatment or prevention of Huntingtons disease, Parkinsons disease, Alzheimers disease, and the Other Neurodegenerative Diseases using an HDAC Inhibitor or any Compound developed pursuant to the Collaboration; provided, however, that the term Field shall cease to include ALS or Dementia if, as to a particular Subject Indication.
'Applicable Field' means the Field, but only as to the disease indications within the Research and Development Program that is the subject of a Back-Out (i.e., the AD R&D Program, the HD R&D Program or the PD R&D Program), in each case including any of the Other Neurodegenerative Diseases.
IPSCIO Record ID: 203362
The Licensor of Denmark grants a co-exclusive, solely with Licensor, license in the Field throughout the Territory under the Licensors Licensed Technology, Licensors Collaboration Technology, and Licensors interest in the Joint Collaboration Technology to conduct the Research Program and to make and use Collaboration Products in connection with the Research Program, each in accordance with the terms of this Agreement.
The patents cover Carbamic acid compounds comprising an ether linkage as HDAC inhibitors – short name HDAC-B (Ethers); an amide linkage as HDAC inhibitors – short name HDAC-E (Amides) ; a sulfonamide linkage as HDAC inhibitors – short name HDAC-F (Sulfonamides); an ester or ketone linkage as HDAC inhibitors – short name HDAC-H (Ketones/Esters); a piperazine linkage as HDAC inhibitors – short name HDAC-1 (Piperazines); and a bicyclic heteroaryl group as HDAC inhibitors – short name HDAC-J (Quinoxalines).
PXD101 is a novel histone deacetylase (HDAC) inhibitor for the treatment of solid and hematological cancers. PXD101 is currently in a Phase I clinical trial in patients with advanced solid tumors and is one of the most advanced HDAC inhibitors in development. HDAC inhibitors are a new class of potential anti-cancer agents that have shown promise in preclinical and clinical studies.
Patent family 'Carbamic acid compounds comprising an amide linkage as HDAC inhibitors' – short name ' HDAC-E (Amides)'
Patent family 'Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors – short name 'HDAC-F (Sulfonamides) '
IPSCIO Record ID: 344538
The collaboration shall continue as stated in the original agreement, with this Pursuing Party change. The original agreement has conditional exclusivity.
The field as identified in the original agreement means the treatment or prevention of Huntingtons disease, Parkinsons disease, Alzheimers disease, and the Other Neurodegenerative Diseases using an HDAC Inhibitor or any Compound developed pursuant to the Collaboration; provided, however, that the term Field shall cease to include ALS or Dementia if, as to a particular Subject Indication.
IPSCIO Record ID: 203375
– Publish the general scientific findings from research related to Licensed Subject Matter and Licensed Products subject to the confidentiality terms, and
– Use Licensed Subject Matter or Identified Products solely for research, teaching and other educationally-related, non-commercial purposes only.
Licensed Product means any compound, assay, method, reagent, technology, or product comprising Licensed Subject Matter pursuant to this Agreement.
Licensed Subject Matter means inventions and discoveries claimed in Patent Rights or covered by Technology Rights within Licensed Field.
Technology Rights means Licensors rights in technical information, know-how, processes, procedures, compositions, devices, methods, formulas, protocols, techniques, software, designs, drawings or data created by Inventors relating to Licensed Subject Matter which are not covered by Patent Rights, but useful.
IPSCIO Record ID: 223149
IPSCIO Record ID: 240578
Licensed Subject Matter means inventions, discoveries, assays and processes covered by Patent Rights and/or Technology Rights within Licensed Field.
The patents are for Methods and Compositions Relating to Muscle Selective Calcineurin Interacting Protein (MCIP).
IPSCIO Record ID: 245875
BACE Collaboration Compound means a compound that is a BACE Inhibitor, and is discovered by either or both Parties or their Affiliates during the Research Term, or is acquired by either or both Parties or their Affiliates during the Research Term, or was discovered by Licensor prior to the Research Term. BACE Collaboration Compounds discovered prior to the Effective Date by Licensor.
BACE Inhibitor means a compound that at Licensor inhibits human BACE enzyme activity by fifty percent (50%) at a concentration (IC50) of less than one micromole per liter ( <l Âµmol/L) in an in vitro assay in which the Licensor inhibitor standard, I-!4848, has an ICso of less than fifteen nanomoles per liter (<15 nmoVL) in an assay following the protocol as currently performed at Vitae and/or a compound that at Licensee inhibits human BACE enzyme activity by fifty percent (50%) at an ICso of less than one micromole per liter (<l Âµmol/L) in in vitro assays in which the Licensee standard inhibitor, N-((1S,2R)-1-benzyl-3- cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino )-N-( (R)-1-phenylethyl)-isophthalamide (compound 3 from Stachel et al. J. Med. Chem. 2004, 47, 6447-6450) has an IC50 of less than or equal to seventy nanomoles per liter (s70 nmol/L) in assays following the protocols as currently performed at Licensee.
Licensee is responsible for the development and commercialization of BACE inhibitors for the treatment of Alzheimer's disease and other forms of dementia.
IPSCIO Record ID: 299249
Licensor grants, commencing at the expiration of the Research Term and for a period of six years thereafter, a non-exclusive, world-wide right and license under the Licensor Patents and Licensor Know-How, and Licensors rights in the Joint Patents and Joint Know-How, solely to discover, synthesize, and, in connection with Licensees activities under this Agreement, make and use Active Compounds for use in the Field.
For the Commercialization License to Licensee, Licensor grants an exclusive, world-wide right and license under the Licensor Patents, the Licensor Know-How and under Licensors rights in the Joint Know-How and Joint Patents, solely to [conduct development on, and to make, have made and use for such purpose, Back-Up Compounds and Collaboration Compounds for use in the Field and to make, have made, import, use, sell and offer for sale Licensed. Products) for use in the Field.
For the Cross-License of Know-How Licensor grants a non-exclusive license under the Licensor Know-How for any purpose or use.
Licensed Product means any product, including any formulation thereof, containing or comprising a Collaboration Compound.
Active Compound means any compound that
— has the ability to inhibit (or, in the case of a prodrug, an active species of which inhibits) cathepsin S with a [K; equal to or less than 100 nM];
— has greater than [100- fold selectivity] for cathepsin S against an [appropriate panel of cathepsins in appropriate assays,] as determined by the JRC; and
— has appropriate [in-cell activity in concentrations of less than IO ÂµMin a relevant cell based assay(s)] selected by the JRC.
Cathepsin S is associated with certain inflammatory diseases, such as arthritis, asthma, atherosclerosis and a variety of autoimmune diseases.
Cysteine proteases are enzymes that are responsible for the cleavage and breakdown of other natural proteins in normal biological processes. In disease conditions, cystein proteases can often be misregulated, providing an entry point for drug intervention. Cathepsin S has been associated with the processing and activation of the antigen receptor called MHC-II, essential for the initiation of both normal and pathological immune responses mediated by T-cells. Drugs designed to inhibit this enzyme may provide a novel method for control of antigen-induced response in multiple inflammatory and autoimmune disease states, the companies believe.
IPSCIO Record ID: 289175
Active Compound shall mean a Compound that modulates a Target, the mechanism of which is a binding interaction with a Target, having a level of activity against a Target, expressed as an IC50, that is – less than forty (40) nanomolar- as measured in the applicable in vitro biochemical assay set forth in the Discovery Plan; and a Compound that modulates at least two of the following receptors TrkA, TrkB or TrkC, the mechanism of which is a binding interaction with the applicable Trk receptor, having a level of activity against the applicable Trk receptor, expressed as an ICso, that is less than forty (40) nanomolar as measured in the applicable in vitro biochemical assay set forth in the Discovery Plan.
Clinical Candidate shall mean, with respect to each Target or Trk, any Active Compound that meets the Clinical Candidate Criteria set forth in the Discovery Plan.
Compound shall mean any one or more chemical entity(ies) made and tested against Trk in the course of Licensors pan-Trk program prior to the Effective Date, or synthesized by Licensor in the course of performing or in connection with the Discovery Program, in each case together with any salt, hydrate, solvate, clathrate, polymorph or isomer thereof.
Product shall mean any pharmaceutical product incorporating as an active ingredient an Active Compound.
Trk shall mean the Trk family of receptors TrkA, Tr kB and TrkC.
— TrkA shall mean the protein known as UniProtKB/Swiss-Prot # P04629.
— TrkB shall mean the protein known as UniProtKB/Swiss-Prot # Q16620.
— TrkC shall mean the protein known as UniProtKB/Swiss-Prot # Q16288.
The Targets are
— The protein family commonly known as Firbroblast Growth Factor Receptors (FGFR),
— The protein commonly known as [p70S6 Kinase], identified with the following SwissProt entries
a) Ribosomal protein S6 kinase beta-1 (P23443)
b) Ribosomal rotein S6 kinase beta-2 (Q9UBS0]— The protein commonly known as Telomerase reverse transcriptase, identified with the following SwissProt entries
a) Telomerase reverse transcriptase (014746)
b) Telomerase protein component 1 (Q99973)
Licensee possesses pharmaceutical research, development and commercialization capabilities, as well as proprietary technology in the field of cancer treatment.